News, views and contacts from the global Drugdevelopment industry
28 July 2017
Industry News

M&As this week: BriaCell Therapeutics, Lentigen Technology
BriaCell Therapeutics plans to acquire Sapientia Pharmaceuticals through its subsidiary BriaCell Therapeutics (BriaCell USA).

Deals this week: eFFECTOR Therapeutics, VenatoRx Pharmaceuticals, Kezar Life Sciences
US-based biotech company eFFECTOR Therapeutics has secured $38.6m in a series C venture financing round led by Pfizer Venture Investments (PVI).

OncoQuest starts enrolment in Phase I/II ovarian cancer trial
Canada-based OncoQuest has started enrolling patients in a Phase I/II clinical trial to evaluate the combination of its antibody oregovomab with Hiltonol as a treatment for ovarian cancer.

Genentech’s Actemra meets primary and secondary endpoints in Phase III trial for GCA
Genentech has reported positive results from the Phase III GiACTA clinical trial of Actemra (tocilizumab) to treat adults with giant cell arteritis (GCA).

Press Releases

Powerful Benchtop Spectrometer for Small Spot Analysis
Supplier of analytical X-ray instrumentation and software PANalytical has announced the introduction of a new Epsilon 1 X-ray fluorescence (XRF) spectrometer.

Huge New Opportunity in Generic Drug Development Created by US FDA
The US market is to gain access to previously unavailable therapeutically equivalent generic drug formulations due to a number of changes.

Tailoring the Properties of New Compounds Using XRD Data Analysis
Understanding the make-up of crystalline structures is a vital aspect of the characterisation of new compounds, and can be regarded as an important first step towards the possibility of tailoring its properties.

Upcoming Events Malvern
Malvern will be hosting a wide range of webinars throughout July and August.

Breaking Down Complex Generics
Pharmaceutical consulting and generic drug professionals: What is your hedge against the increasingly crowded traditional drug markets?

White Papers

Customised Crystallisation and Filtration System
Systag's crystallisation and filtration system helps increase your flexibility, productivity, and optimises your...

Drug Labeling Specialist on New Pregnancy Labeling Rules
On 30 June, 2015, new pregnancy labeling rules for prescription drugs took effect, marking the demise of pregnancy categories (A, B, C, D, X), which have been in use since...

Sartorius Lab Instrument's Cubis® Balance Range Meets the Cleanability Requirements of the Pharmaceutical Industry
Balances in Satorius Lan Instrument's Cubis® product range have been designed for the demanding pharmaceutical environment, which is regulated by good manufacturing practices (GMP) and...

Gold Nanoparticle Applications and Characterisation by Nanoparticle Tracking Analysis
Gold nanoparticles are one of the most popular and extensively researched type of...

Characterisation Information of Critical Excipients for Sourcing Critical Raw Materials
The increasing complexity of large molecule and cell-based therapeutics calls for an evolution in our understanding of the impurity and functional contributions of each formulation...

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.